You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The offering consists of 2 million common shares offered by the company and 1.5 million common shares offered by selling shareholders at a price of $14 per share.
Of the 28 companies in the index, 18 firms saw their stock prices increase, while 10 firms' share prices decreased.
The cancer molecular diagnostics firm said it will use the proceeds from the offering to support its R&D activities and for general corporate purposes.
CareDx, which focuses on transplant medicine, said it intends to use the proceeds from the offering for working capital and general corporate purposes.
ArcherDx has leveraged next-generation sequencing to develop and commercialize more than 325 research-use-only products and a pan-solid tumor diagnostic test.
The Swedish company said it will use the funds in part to accelerate the commercialization of its PanCan-d test for early-stage pancreatic cancer detection.
he firm will use the proceeds to expand manufacturing capacity for its existing and in-development COVID-19 assays.
The company, along with Softbank Investment Advisers, is offering a total of 11.5 million shares of its common stock at $84 per share.
The company plans to use the proceeds for general product R&D, for reimbursement studies in the US, and for preparation for potential COVID-19 testing.
BD has also granted the offerings' underwriters an option to purchase up to an additional $450 million of common stock and depositary shares.